AIQ Global secures new AMA Category III CPT code for TRAQinform IQ

3 March 2026 — The American Medical Association has approved a new Category III CPT code describing lesion-level analysis of treatment-response heterogeneity in advanced metastatic cancer, as performed by AIQ Global’s FDA-cleared TRAQinform IQ technology. President and CEO Eric Horler: “This CPT code represents a critical step toward broader clinical adoption of technology that can transform care for patients with advanced cancer.”

Source: https://www.prnewswire.com/news-releases/aiq-solutions-announces-a-new-category-iii-cpt-code-for-determining-heterogeneity-of-change-across-all-lesions-for-advanced-metastatic-cancer-used-with-traqinform-iq-technology-302702706.html

Albion Trinity Capital is an investor in AIQ Global.